



BLA 125427/S-121

**SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING COMMITMENT**

Genentech, Inc.
Attention: Monica Shah
Regulatory Program Management
1 DNA Way
South San Francisco, CA 94080

Dear Monica Shah:

Please refer to your supplemental biologics license application (sBLA) received July 31, 2024, and your amendments, submitted under section 351(a) of the Public Health Service Act for Kadcyła (ado-trastuzumab emtansine) sterile lyophilized single use vial.

This Prior Approval sBLA provides for updates to the Clinical Studies section (14) of the US Prescribing Information to include additional overall survival data from Study BO27938, entitled; “A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.” Additionally, the Clinical Pharmacology Immunogenicity section was updated and moved from Section 6 to 12 to align with current labeling practices.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Prescribing Information) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effectuated” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplement application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING COMMITMENT

We have received your submission dated July 31, 2024, containing the final report for the following postmarketing commitment listed in the May 3, 2019, approval letter for BLA 125427/S-105.

3581-1 Submit the final overall survival (OS) analysis and datasets with the final report from KATHERINE clinical trial (Study BO27938) entitled; “A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2- Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.”

We have reviewed your submission and conclude that the above commitment was fulfilled.

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our May 3, 2019, letter. You are not required to report on the status of closed (released or fulfilled) PMRs/PMC in your annual report required under 21 CFR 601.70 of the FD&CA.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Sso (Anna) Lee, Regulatory Project Manager, at (301) 796-0282 or at Sso.Lee@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Christy Osgood, MD
Supervisory Associate Director
Division of Oncology 1
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

CHRISTY L OSGOOD
05/14/2025 10:29:46 AM